RxDoctor Payments Data

Andrew Dargan, MD

Gastroenterology · Philadelphia, PANPI 1700223013

Payments from drug & device makers

$10,138in general payments, 2019–2025

Across 511 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Medical Systems Corporation$2K
  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$923
  • Johnson & Johnson$547
  • Regeneron Healthcare Solutions, Inc.$403
  • plus $3K from 31 others

What the payments were for

  • Consulting fees$2,42024%
  • Food & beverage$7,69576%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,138 in reported general payments places this provider in the 75th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$231,966
Medicare patients
568
Services billed
5,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin33$87,745
CreonLipase/Protease/Amylase22$83,828
ZenpepLipase/Protease/Amylase14$60,195
LinzessLinaclotide47$49,416
TrulancePlecanatide11$15,235
Dexlansoprazole DrDexlansoprazole23$10,401
Lubiprostone36$6,579
Colestipol Hcl63$4,821
Omeprazole311$4,779
Dicyclomine Hcl111$4,071
Pantoprazole Sodium182$3,001
Famotidine193$2,936
Esomeprazole Magnesium43$2,879
Sucralfate73$2,624
Ondansetron OdtOndansetron21$946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,706$133,24469 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,293$102,97944 claims
Aimmune Therapeutics, Inc.Zenpep$194$60,19514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →